Frontierby eninvs

Language: EN · RU

← Region

Genomma Lab Internacional (LAB) MXN

Genomma Lab is a pharmaceutical and consumer-health company focused on OTC drugs, personal care and branded generics in Mexico and abroad.

At a glance: strengths & risks
✓Revenue growing (+22595% y/y, Q1 2026)✓Profit growing (+99078% y/y, Q1 2026)✓Margins improving (24%→87%, Q1 2026)✓Low leverage (0.5x EBITDA)✗Pricier than own history (P/E 24.9 vs avg 13.6)

Sector: Consumer health

MX_LAB

Price chart

12.64 MXNDay -2.09%

Key metrics

Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.

Market

Price
12.64 MXN · -2.09%
Market cap
12.4 bn MXN

Growth

Δ revenue y/y
—
Δ EBITDA y/y
—

Multiples

P/E (LTM)
24.9x
3y avg: 13.6x
P/B (FY)
1.1x
P/E (ann.)
0.0x
EV/EBITDA (LTM)
—
3y avg: 5.3x

Cash return

Dividend yield
6.3%
FCF yield (LTM)
—

Value creation

fundamental value/yr, % of market cap
Value created / year
+4.7%
↓ details

Liquidity

Daily turnover (listing)
27.7 mln MXN

Shares: yahoo_fundamentals_timeseries/LABB.MX

Amounts: USD (converted) · As reported
Converted modes use NBK / ECB-linked rates: balance sheet date for BS items, period average for P&L and cash flow (see filing row evidence). As reported keeps each row in its filing currency.

Financial results

Monetary columns are in B MXN, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.

DatePeriodStatusRevenueB MXNOperating profitB MXND&AB MXNEBITDAB MXNNet profitB MXNOperating CFB MXNCapex + M&AB MXNAssetsB MXNEquityB MXNROE (annualized)Net debtB MXNSource
2026-03-31Q1 2026 (3M)PARTIAL1000.0
y/y —
874.4
y/y —
0.1
y/y -6.5%
874.5
y/y —
494.6
y/y —
-229.2-80.8—
y/y —
—
y/y —
—-1191.9Report (PDF)
2025-12-31FY 2025 (12M)OK—
y/y -5.7%
—
y/y -3.8%
—
y/y 5.4%
—
y/y -3.0%
—
y/y 8.1%
——23.8
y/y 3.5%
11.1
y/y 2.1%
14.4%1.9Link
2025-06-30Q2 2025 (3M)OK4.7
y/y —
1.0
y/y —
0.1
y/y —
1.1
y/y —
0.4
y/y —
0.50.024.2
y/y —
11.2
y/y —
12.7%-2.6Report (PDF)
2025-03-31Q1 2025 (3M)OK4.4
y/y —
1.0
y/y —
0.1
y/y —
1.1
y/y —
0.5
y/y —
-0.2-0.124.1
y/y —
11.1
y/y —
18.1%-2.2Report (PDF)
2024-12-31FY 2024 (12M)OK18.6
y/y 13.0%
3.9
y/y 22.0%
0.4
y/y 58.2%
4.3
y/y 24.4%
1.5
y/y 45.5%
3.0-0.723.0
y/y 11.2%
10.9
y/y 16.0%
14.7%2.8Link
2023-12-31FY 2023 (12M)OK—
y/y —
—
y/y —
—
y/y —
—
y/y —
—
y/y —
——20.7
y/y —
9.4
y/y —
10.4%2.7Link
2023-03-31Q1 2023 (3M)OK4.2
y/y —
0.8
y/y —
0.0
y/y —
0.8
y/y —
0.4
y/y —
——21.8
y/y —
10.4
y/y —
—0.0Report (PDF)

Net debt structure (leases included, IFRS 16) 2026-03-31

Short-term debt (incl. ST leases)1 876 579
Long-term debt (incl. LT leases)4 729
− Cash & equivalents3 073 169
Net debt-1 191 861

Net debt / LTM EBITDA: -1.4x

Revenue & EBITDA

RevenueEBITDA

Quarterly values ($ mln)

0200 000400 000600 000800 0001 000 0002023 q12024 FY2025 q12025 q22026 q1

Cash flow

FCF ($ mln)

-400 000-300 000-200 000-100 00002023 q12024 FY2025 q12025 q22026 q1

Net debt / cash ($ mln)

-1 250 000-1 000 000-750 000-500 000-250 00002023 q12023 q42024 FY2025 q12025 q22025 q42026 q1

Profit and cash

Profit is cash-backed
In a typical year of 2023–2025 operating cash flow came to 2.03x of reported net profit.
year202320242025
cash flow / profit2.19x2.03x1.27x
accruals, % of assets-5.9%-6.7%-1.8%
Last twelve months (to - Q1 2025): -0.46x of profit came back as operating cash flow.
net debt / EBITDA 0.5x
● Over the last twelve months operating cash flow covered -46% of profit, against 2x across the annual window.
Read from the reported annual statements: cash flow / profit is the median of the yearly operating cash flow over net profit for the years shown; accruals are (profit − operating cash flow) / assets, the classic gap between what was booked and what was collected. A gap can be growth in working capital, capitalised costs, revaluations or profit from associates — the panel points at it, the statements explain it. Not investment advice.

Research & reviews

Our earnings breakdowns and investment notes on this issuer.

All research →

Fundamental value creation

Value the company creates per year, as a % of market cap

Value created per year: +4.7%

How this was calculated
1. EBITDA growth (latest quarter YoY, annualised)
[EBITDA latest qtr − EBITDA year-ago qtr] × annualisation X (2026-03-31 vs 2025-03-31)
= (874 491 − 1 058) × 1.00
130
2. Current EV/EBITDA (LTM)
(Market cap + Net debt) ÷ EBITDA (LTM)
= (12 359 + -1 191 861) ÷ 877 475
0.0x
3. Target multiple
(Current EV/EBITDA + 9) ÷ 2
= (0.0 + 9) ÷ 2
4.5x
4. Cash flow (balance method, LTM)
Net-debt reduction + dividends + buybacks − equity issuance
= 1 189 704 + 0 + 0 − 0
0
5. Value created per year
(EBITDA growth × Target multiple + Cash flow − Dilution) ÷ Market cap
= (130 × 4.5 + 0) ÷ 12 359
+4.7%

Amounts in millions of the reporting currency. EBITDA growth is the latest quarter vs the same quarter a year ago, annualised.

Caveats:

  • capex unavailable — FCF approximated by FY OCF (ended 2025-12-31, before the latest reported period 2026-03-31)
  • dividends/buybacks not in data - balance cash flow uses net-debt change only
  • net-cash rise stripped: net debt fell while EBITDA declined and no share dilution measured (likely equity raise / recapitalisation)
  • EBITDA-growth term damped to the multi-year FY trend SIZE but kept the latest period direction (up) - the trend pointed the other way

Revenue growth & acceleration

Growth decelerating ▼
Last-year revenue growth -6% vs +13% the year before — a -18.7 pp move. 3-year CAGR —.
revenue growth by year: 2024 +13% · 2025 -6%
The growth-acceleration signal behind the GARP+acceleration strategy — it favours companies whose revenue growth is speeding up and flags those slowing down (the second derivative of growth).

Dividends

Paid (completed)

DatePer shareDetailsStatusSource
2026-06-260.2 MXNEx-dividend: 0.2 MXN per sharePaidYahoo Finance (ex-div)
2026-03-300.2 MXNEx-dividend: 0.2 MXN per sharePaidYahoo Finance (ex-div)
2025-12-230.2 MXNEx-dividend: 0.2 MXN per sharePaidYahoo Finance (ex-div)
2025-09-180.2 MXNEx-dividend: 0.2 MXN per sharePaidYahoo Finance (ex-div)
2025-06-300.2 MXNEx-dividend: 0.2 MXN per sharePaidYahoo Finance (ex-div)
2025-03-130.2 MXNEx-dividend: 0.2 MXN per sharePaidYahoo Finance (ex-div)
2024-12-170.2 MXNEx-dividend: 0.2 MXN per sharePaidYahoo Finance (ex-div)
2024-09-130.2 MXNEx-dividend: 0.2 MXN per sharePaidYahoo Finance (ex-div)
2024-06-200.2 MXNEx-dividend: 0.2 MXN per sharePaidYahoo Finance (ex-div)
2024-03-210.1961 MXNEx-dividend: 0.1961 MXN per sharePaidYahoo Finance (ex-div)
2023-12-220.1961 MXNEx-dividend: 0.1961 MXN per sharePaidYahoo Finance (ex-div)
2023-09-280.1961 MXNEx-dividend: 0.1961 MXN per sharePaidYahoo Finance (ex-div)
2023-06-050.1961 MXNEx-dividend: 0.1961 MXN per sharePaidYahoo Finance (ex-div)
2022-11-090.3817 MXNEx-dividend: 0.3817 MXN per sharePaidYahoo Finance (ex-div)
2022-06-060.3817 MXNEx-dividend: 0.3817 MXN per sharePaidYahoo Finance (ex-div)
2021-12-080.3817 MXNEx-dividend: 0.3817 MXN per sharePaidYahoo Finance (ex-div)
2021-12-010.7634 MXNEx-dividend: 0.7634 MXN per sharePaidYahoo Finance (ex-div)

KASE: status follows wording in the news headline (paid vs intends to pay). Yahoo: amounts are cash dividends per share on ex-dividend dates (UTC calendar date). stockscope.uz (UZ): amounts are per share in UZS by publication date (not necessarily ex-div).

Investor reporting (IR): https://inversionistas.genommalab.com/en/investors/

Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)

Financial results, valuation multiples (P/E, P/B, EV/EBITDA), profitability and dividend yield of Genomma Lab Internacional (LAB) — from primary filings.

Frequently asked questions

What is Genomma Lab Internacional (LAB)'s P/E ratio?
Genomma Lab Internacional (LAB) trades at a P/E of 24.9x (price to trailing 12-month earnings).
What is Genomma Lab Internacional (LAB)'s P/B ratio?
Genomma Lab Internacional (LAB) trades at a P/B of 1.1x.
What is Genomma Lab Internacional (LAB)'s dividend yield?
Genomma Lab Internacional (LAB)'s trailing 12-month dividend yield is 6.3%.
What is Genomma Lab Internacional (LAB)'s return on equity (ROE)?
Genomma Lab Internacional (LAB)'s ROE is 14.4%.
What is Genomma Lab Internacional (LAB)'s market capitalization?
Genomma Lab Internacional (LAB)'s market cap is 12.4 bn MXN.

See also: Mexican Stocks (2026): Quality Value and the Nearshoring Trade · The Cheapest Stocks in the World (2026): What Value Investing Says About Buying Cheap · global valuation map